Sinarest wins ‘Brand of the Year’ for marketing excellence for seventh year

Sinarest has won the prestigious ‘Brand of the Year’ award for marketing excellence for an unprecedented seventh year in a row at the AWACS-Pharmarack Awards held in Mumbai on 22nd November, 2022. Sinarest, introduced in 1983 in India, by Centaur Pharma, is the leader in the prescription anti-cold market for 26 years amid intense competition from international, domestic, regional, OTC and alternate therapy brands, a statement from Centaur Pharma notified.

Brand Sinarest registered a robust MAT growth of 57 per cent in FY 2021-22, and holds a national market share of over 40 per cent by value and volumes. It is the number one prescribed anti-cold brand across specialities like ENT surgeons, paediatricians, consulting physicians, chest physicians and family physicians. Two prescriptions of Sinarest are written every second by doctors in India. It is freely available in all eight lakh pharmacies in India, and is also the number one prescribed anti-cold brand in Uganda and Cambodia, the statement claimed.

SD Sawant, Managing Director, Centaur, said in the statement, “Sinarest has been marketed based on evolving scientific research and rationale. Sinarest has earned the trust of doctors by consistently delivering on its promise of efficacy, safety and relief over the past four decades.”

Centaur Pharma also won the First Runner Up award for the AWACS-Pharmarack “Most Optimised Supply Chain” for their outstanding performance in distribution and logistics.

Sanjay Shinde, GM, Distribution, Centaur, said in the statement, “We have built efficient and effective processes and templates that deliver service excellence in supply chain. We are delighted that our efforts have been recognised and rewarded by AWACS-Pharmarack.”



Read More: Sinarest wins ‘Brand of the Year’ for marketing excellence for seventh year

2022-11-24 03:15:11

Notify of
Inline Feedbacks
View all comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More